# HawkEye 360, Inc.: financial statements, quarterly

HAWK · NYSE · CIK 1750704 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hawk.md) · [Financials](/companies/hawk/financials.md) · [Filings](/companies/hawk/filings.md) · [Insiders](/companies/hawk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hawk/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [23.0](/filings/0001750704-26-000014.md) | [26.6](/filings/0001750704-26-000022.md) | [49.8](/filings/0001750704-26-000014.md) | [49.8](/filings/0001750704-26-000022.md) |
| Research and development | $m | [6.9](/filings/0001750704-26-000014.md) | [5.9](/filings/0001750704-26-000022.md) | [9.2](/filings/0001750704-26-000014.md) | [8.2](/filings/0001750704-26-000022.md) |
| Selling, general and administrative | $m | [7.9](/filings/0001750704-26-000014.md) | [8.8](/filings/0001750704-26-000022.md) | [18.1](/filings/0001750704-26-000014.md) | [25.0](/filings/0001750704-26-000022.md) |
| Operating income | $m | [(2.1)](/filings/0001750704-26-000014.md) | [0.8](/filings/0001750704-26-000022.md) | [(5.6)](/filings/0001750704-26-000014.md) | [(11.5)](/filings/0001750704-26-000022.md) |
| Interest expense | $m | [0.0](/filings/0001750704-26-000014.md) | [0.0](/filings/0001750704-26-000022.md) | [1.3](/filings/0001750704-26-000014.md) | [0.9](/filings/0001750704-26-000022.md) |
| Income tax | $m | [0.0](/filings/0001750704-26-000014.md) | [0.0](/filings/0001750704-26-000022.md) | [(0.0)](/filings/0001750704-26-000014.md) | [0.3](/filings/0001750704-26-000022.md) |
| Net income | $m | [(1.6)](/filings/0001750704-26-000022.md) | [1.6](/filings/0001750704-26-000022.md) | [(9.0)](/filings/0001750704-26-000022.md) | [(15.3)](/filings/0001750704-26-000022.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001750704-26-000014.md) | [0.01](/filings/0001750704-26-000022.md) | [(1.14)](/filings/0001750704-26-000014.md) | [(0.07)](/filings/0001750704-26-000022.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0001750704-26-000014.md) | [0.02](/filings/0001750704-26-000022.md) | [(1.14)](/filings/0001750704-26-000014.md) | [(0.07)](/filings/0001750704-26-000022.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [71.3](/filings/0001750704-26-000014.md) | [94.9](/filings/0001750704-26-000022.md) | [92.7](/filings/0001750704-26-000022.md) | [106](/filings/0001750704-26-000014.md) | [503](/filings/0001750704-26-000022.md) |
| Current assets | $m | not reported | not reported | not reported | [169](/filings/0001750704-26-000022.md) | [172](/filings/0001750704-26-000014.md) | [573](/filings/0001750704-26-000022.md) |
| Total assets | $m | not reported | not reported | not reported | [490](/filings/0001750704-26-000022.md) | [490](/filings/0001750704-26-000014.md) | [904](/filings/0001750704-26-000022.md) |
| Current liabilities | $m | not reported | not reported | not reported | [40.7](/filings/0001750704-26-000022.md) | [25.0](/filings/0001750704-26-000014.md) | [58.5](/filings/0001750704-26-000022.md) |
| Total liabilities | $m | not reported | not reported | not reported | [149](/filings/0001750704-26-000022.md) | [134](/filings/0001750704-26-000014.md) | [109](/filings/0001750704-26-000022.md) |
| Long-term debt | $m | not reported | not reported | not reported | [46.3](/filings/0001750704-26-000022.md) | [46.6](/filings/0001750704-26-000014.md) | [0.0](/filings/0001750704-26-000022.md) |
| Shareholders' equity | $m | [(114)](/filings/0001750704-26-000022.md) | [(115)](/filings/0001750704-26-000022.md) | [(112)](/filings/0001750704-26-000022.md) | [(107)](/filings/0001750704-26-000022.md) | [(110)](/filings/0001750704-26-000022.md) | [795](/filings/0001750704-26-000022.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.5)](/filings/0001750704-26-000014.md) | [4.6 d](/filings/0001750704-26-000022.md) | [(3.3)](/filings/0001750704-26-000014.md) | [11.6 d](/filings/0001750704-26-000022.md) |
| Capital expenditure | $m | [3.2](/filings/0001750704-26-000014.md) | [5.9 d](/filings/0001750704-26-000022.md) | [4.1](/filings/0001750704-26-000014.md) | [6.2 d](/filings/0001750704-26-000022.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.2](/filings/0001750704-26-000014.md) | [12.2](/filings/0001750704-26-000022.md) | [8.4](/filings/0001750704-26-000014.md) | [61.9](/filings/0001750704-26-000022.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 97,965,552 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001750704-26-000022.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.